Bioequivalence and Bioavailability Forum

drugs of long half life [Design Issues]

posted by jag009  – NJ, 2013-04-05 19:45 (4461 d 07:33 ago) – Posting: # 10359
Views: 7,962

Hi Ken,

Specifically what are you looking for? The sections in that book seem sufficient in terms of study design and the approach. I agree that the stat description is a little vague as it only highlights variability, sample size and what is needed to calculate the 90%CI (Which I agree with Helmut that the wording is wrong).

Are you using WinNonlin or SAS? I recall WinNonlin can perform parallel design analysis (See D_labes response in this thread about SAS). I think there have been several discussions about parallel design in Helmut's crib here () so you might want to search around.

John
Thanks

John

Complete thread:

• drugs of long half life Ken Peh 2013-03-31 06:43 [Design Issues] 
  • drugs of long half life jag009 2013-04-02 15:17
    • drugs of long half life Helmut 2013-04-02 15:34
      • drugs of long half life jag009 2013-04-02 16:01
        • drugs of long half life Helmut 2013-04-02 16:40
          • parallel FDA d_labes 2013-04-04 08:33
            • parallel FDA jag009 2013-04-05 18:01
            • parallel FDA jag009 2013-04-05 21:10
              • random repeated parallel FDA d_labes 2013-04-08 08:29
                • Proc Mixed: random repeated parallel FDA jag009 2013-04-08 15:36
                  • Proc Mixed: parallel groups with different variabilities d_labes 2013-04-08 16:41
                    • Proc Mixed: parallel groups with different variabilities jag009 2013-04-08 20:22
    • drugs of long half life Ken Peh 2013-04-04 15:03
      • drugs of long half lifejag009 2013-04-05 17:45